SEC Form 4 · accession 0000911916-16-000600
CoLucid Pharmaceuticals, Inc. · CLCD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Raymond Skwierczynski
Officer — Head,Pharmaceutical Operations
Period of report
Jun 30, 2016
Accepted (ET)
Jun 30, 2016 · 4:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348649
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 30, 2016 | S | 516 | $7.011 | D | 2,737 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Skwierczynski on June 1, 2016.
- F2Represents the sale of 516 shares in multiple transactions, ranging in price from $7.00 to $7.71 per share, resulting in a weighted average sale price of $7.011. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.